Most people have a hard time thinking of arsenic as a cure of any kind. Indeed, the association that comes to mind is the poisoning death of historical and literary characters such as Madame Bovary and Napolé on Bonaparte. Arsenic acts by its high affinity for the sulfhydryl groups of bioenzymes, resulting in various harmful effects through inhibiting the activities. However, it is also one of the oldest medicines in the world. It was first mentioned by , who used realgar and orpiment pastes to treat ulcers in western medicine. In line with the Chinese philosophy, ''fight poison with poison,'' arsenic was also used for treating diseases in ancient China. Arsenic pills for the treatment of periodic fever were recorded in the Chinese Nei Jing Treaty (263 BC). Hong Ge (284-364 AD), a Taoism alchemist, used arsenic (As 4 S 4 ) as a disinfector and obtained pure arsenic from the compounds by heating, documented in his work Baopuzi Inner Chapter. Si-Miao Sun (581-682 AD) purified a medicine composed of realgar, orpiment, and arsenic in treating malaria, whereas Shi-Zhen Li (1518-1593 AD) in the Ming Dynasty described the use of arsenic as a remedy for a variety of diseases in his pharmacopedia. The exploration of using arsenic to treat leukemia started in the 1970s in China. At the time, Tai-Yun Han, a pharmacist of the First Affiliated Hospital of Harbin Medical University, happened to learn that a folk remedy composed of arsenic trioxide (ATO), mercury chloride, or toad venom had some effects on some cancer cases. He then made solutions with the same components and named them Ailing Solutions. His colleague, Ting-Dong Zhang, explored the effect of the solution containing ATO and mercury on myeloid leukemia patients and observed some promising effects. However, as the mode of action of ATO was not clear, the regimen was not widely applied.
APL, also known as the M3 subtype of acute myeloid leukemia (AML-M3), accounts for 10% of all AML cases and has a very severe natural course. APL was once one of the most lethal forms of leukemia because of the heavy burden of leukemia blasts, in which myeloid differentiation is blocked at the stage of promyelocytes, and because of the presence of hemorrhagic syndrome. In the 1970s, the combination of anthracyclines and cytosine arabinoside was adopted as the mainstream treatment, but there was high early mortality due to severe hemorrhage often exacerbated by chemotherapy. APL treatment took a turn for the better in the early 1980s, owing to the clinical application of all-trans retinoic acid (ATRA) by Zhen-Yi Wang's team at Shanghai Institute of Hematology, and the drug could result in a complete remission (CR) rate of over 90%. We were very proud to contribute to this breakthrough while pursuing our Master's degree in Wang's team. In 1980, Professor Zhen-Yi Wang and Zhu Chen set the following objectives: identify factors promoting leukemic cell differentiation; explore treatment of leukemia with regulatory mechanisms other than chemotherapy. Led by Prof. Wang, our team screened a group of drugs and finally discovered the effect of ATRA in breaking the differentiation blockade in leukemic cells. Later, we further explored the pathogenesis of APL and the mechanisms of ATRA with cytogenetic and molecular biological techniques. While it was exciting to successfully apply the notion of differentiation induction to treat leukemia for the very first time, we The devil was resilient, but how should we strike back? At a conference held in 1994, Sai-Juan learned about the earlier attempt of treating leukemia, APL in particular, with ATO from colleagues in Harbin Medical University. This was intriguing, and we almost immediately thought of the possibility of using ATO to combat ATRA resistance. The earlier experience of Zhu as a barefoot doctor in the countryside, during which he made the most of limited, and often not ideal, resources to treat patients, spoke to him that this was the right direction. Meanwhile, as hematologists received scientific training in both China and Europe, we realized it was a bold idea given the potential toxicity, and rigorous study of its mechanism and efficacy is the only way to move forward. Soon, we established collaboration with Ting-Dong Zhang and got pure ATO solution from a spin-off company of Harbin Medical University. We then launched a systematic study on the cellular and molecular mechanisms of the effect of arsenic in APL. We found that ATO potently induced APL cell differentiation and apoptosis by targeting PML-RARa, the oncogenic driver specific for APL. We also discovered that this effect resulted from a selective action of arsenic on the PML, but not RARa moiety, of the fusion protein, and our follow-up studies identified the exact interacting site, structural changes of the oncoprotein upon interacting with 
''The healing effect of poisoning the devil could go a long way.''
arsenic, and the downstream effect triggering protein degradation that leads to APL cell differentiation and apoptosis. These mechanistic studies paved the way for clinical application of arsenic therapy.
In 1995, we conducted the clinical trial of ATO in a series of APL patients relapsed after ATRA and chemotherapy. Among the initial 10 cases treated with ATO alone, CR was achieved in nine. We also demonstrated that the use of arsenic was relatively safe from the pharmacokinetic aspect. Next, we applied ATO on newly diagnosed APL patients. In the next three years, we were able to achieve CR in > 70% of treatment-naive patients and > 85% of relapsed patients. By using PML-RARa transcripts as a biomarker, molecular remission was confirmed, along with phenotypic remission. Our hard work at both the basic mechanistic and the clinical fronts paid off. In August 1999, ATO was approved as a new therapeutic reagent for treating APL by the State Food and Drug Administration of China.
Knowing that cancer cells are hard to eradicate, we have been following up on the clinical application of ATO over the years. Accumulating clinical data suggested that ATO monotherapy could achieve a relatively long-term survival in only a part of cases, whereas a considerable number of patients would relapse again, which showed that arsenic alone, just as ATRA, is not a panacea for APL. Inspired by our earlier clinical observation back in 1994-1998 that 5 out of 5 cases treated with both ATO and ATRA obtained CR, we started to explore the underlying mechanisms that might explain and further support the potential synergy between the two treatments. It is worth mentioning that our long-term collaborator Hugues de Thé and his team reported that combining ATRA and ATO could specifically target leukemia-initiating cells. In the meantime, we discovered that ATRA mainly relieves transcriptional repression, whereas ATO modulates protein network. These two layers of regulation result in cellcycle arrest and differentiation. A striking converging point is the degradation of PML-RARa, with ATRA targeting the RARa and ATO targeting the PML moieties.
Saijuan and Zhu in their own laboratory.
''Looking back to our scientific career, we have benefited a lot from the integration of western and eastern wisdoms.''
Encouraged by these insights, in 2000, we launched a clinical trial with the combination of ATRA and ATO as the front-line therapy-in which ATO was originally used only for relapsed patientsfor newly diagnosed APL, and we found in 2004 that among the 20 patients receiving the combinatory therapy, the durable CR rate with a median follow-up time of 18 months was 100%, whereas in control groups receiving ATRA or ATO treatment alone, several patients relapsed. In view of these data, we extended the combination of ATRA+ATO based therapy to all newly diagnosed APL patients in the next 5 years. In 2009, we reported the exciting clinical follow-up results: 5-year relapse-free survival rate of 94.8 ± 2.5% and overall survival rate of 97.4 ± 1.8% in patients who achieved CR. A subsequent multi-center study on 535 newly diagnosed APL patients led by our team confirmed an over 90% 5-year disease-free survival rate in APL patients. The dramatic effect of this synergistic targeted therapy was confirmed by hematologists and oncologists around the world, including the Australia APML4 protocol led by Iland and the Italian/German trial led by Prof. Lo Coco, both of which yielded impressive outcomes in ATRA+ATO based therapy for APL. Indeed, in 2014, ATRA/ATO synergistic targeted therapy was recommended by the USA National Comprehensive Cancer Network (NCCN) as the first choice for APL treatment. The Italian/German group very recently found that long-term survival can be achieved in low-and intermediate-risk APL cases without chemotherapy, and the same results were also observed in the latest APL2012 trial in China.
Looking back to our scientific career, we have benefited a lot from the integration of western and eastern wisdoms. The Chinese philosophy has taught us how to think in a dialectic way, particularly in exploring the therapeutic value of a poison. It is tricky to practice the idea of ''fighting poison with poison,'' but if you do it right and carefully, you may just achieve the most thrilling success: saving lives. On the other hand, modern analytical thinking and the appreciation on the power of ever-advancing technology from the western scientific training have enabled us to take a close look at the molecular movement of the devil so that we could make informed predictions each step of the way, confidently embracing the positive outcome and breaking new grounds. Indeed, our recent application of a systems biology approach allowed the discovery of hundreds of potential target proteins for the action of ATO, including key players in the development of solid tumors. We are optimistic that the healing effect of poisoning the devil could go a long way, and we are just at the start of the journey.
